Transient delivery of CRISPR‐based genome editing effectors is important to reduce off‐
target effects and immune responses. Recently extracellular vesicles (EVs) have been …

The use of biomaterials in delivering CRISPR/Cas9 for gene therapy in infectious diseases
holds tremendous potential. This innovative approach combines the advantages of …

Safe and efficient intracellular delivery of CRISPR/Cas9 is a key step for effective therapeutic
genome editing in a wide range of diseases. This remains challenging due to multiple …

CRISPR/Cas9 genome editing is a very promising avenue for the treatment of a variety of
genetic diseases. However, it is still very challenging to encapsulate CRISPR/Cas9 …

CRISPR–Cas9 is a revolutionary genome-editing technology that has enormous potential
for the treatment of genetic diseases. However, the lack of efficient and safe, non-viral …

Clustered regulatory interspaced short palindromic repeats or CRISPR/Cas9 has emerged
as a potent and versatile tool for efficient genome editing. This technology has been …

Extracellular vesicles (EVs) are small lipid-enclosed particles that can carry various types of
cargo, including proteins, nucleic acids and metabolites. They are known to be released by …

The method of delivery of CRISPR-Cas9 into target cells is a strong determinant of efficacy
and specificity in genome editing. Even though high efficiency of Cas9 delivery is necessary …

Engineered extracellular vesicles (EVs) are considered excellent delivery vehicles for a
variety of therapeutic agents, including nucleic acids, proteins, drugs, and nanomaterials …

Extracellular vesicles (EVs) hold great promise for transporting CRISPR–Cas9 RNA-guided
endonucleases (RNP) throughout the body. However, the cell-selective delivery of EVs is …